AR031104A1 - Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi - Google Patents
Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensiInfo
- Publication number
- AR031104A1 AR031104A1 ARP010101902A ARP010101902A AR031104A1 AR 031104 A1 AR031104 A1 AR 031104A1 AR P010101902 A ARP010101902 A AR P010101902A AR P010101902 A ARP010101902 A AR P010101902A AR 031104 A1 AR031104 A1 AR 031104A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- agent
- carboxialquileter
- antihipertensive
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 229940030600 antihypertensive agent Drugs 0.000 abstract 2
- 239000002220 antihypertensive agent Substances 0.000 abstract 2
- -1 carboxyalkyl ether Chemical compound 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composicion farmacéutica que comprende: (a) una cantidad de un carboxialquiléter o una sal de adicion farmacéuticamente aceptable de él; (b) una cantidad de un agente antihipertensivo o una sal de adicion farmacéuticamente aceptable de él, y (c) un portador o diluyente farmacéuticamente aceptable. Dicha composicion farmacéutica comprende un compuesto de la formula (1): en donde n y m son independientemente numeros enteros de 2 a 9 ; R1, R2, R3, y R4 independientemente son alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, y R1 y R2 junto con el carbono al cual están unidos pueden completar un anillo carbocíclico que tiene 3 a 6 átomos. Uso de un compuesto para fabricar una composicion farmacéutica para tratar enfermedades vasculares en un mamífero que necesita el tratamiento. Equipo para lograr un efecto terapéutico en un mamífero que comprende una cantidad de carboxialquiléter, una cantidad de agente antihipertensivo y un medio de recipiente para contener dicha primer y segundas formas de dosificacion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19985500P | 2000-04-26 | 2000-04-26 | |
| US24228000P | 2000-10-20 | 2000-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031104A1 true AR031104A1 (es) | 2003-09-10 |
Family
ID=26895229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101902A AR031104A1 (es) | 2000-04-26 | 2001-04-25 | Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1280522B1 (es) |
| JP (1) | JP2003531170A (es) |
| KR (1) | KR20020091245A (es) |
| CN (1) | CN1426299A (es) |
| AP (1) | AP2002002665A0 (es) |
| AR (1) | AR031104A1 (es) |
| AT (1) | ATE283691T1 (es) |
| AU (1) | AU2001247658A1 (es) |
| BG (1) | BG107264A (es) |
| BR (1) | BR0110234A (es) |
| CA (1) | CA2405559A1 (es) |
| CZ (1) | CZ20023459A3 (es) |
| DE (1) | DE60107559T2 (es) |
| DO (1) | DOP2001000150A (es) |
| EA (1) | EA005245B1 (es) |
| EE (1) | EE200200611A (es) |
| ES (1) | ES2231470T3 (es) |
| HR (1) | HRP20020936A2 (es) |
| HU (1) | HUP0300403A3 (es) |
| IL (1) | IL152474A0 (es) |
| IS (1) | IS6570A (es) |
| MA (1) | MA26894A1 (es) |
| MX (1) | MXPA02009662A (es) |
| NO (1) | NO20025135L (es) |
| NZ (1) | NZ521713A (es) |
| OA (1) | OA12252A (es) |
| PA (1) | PA8516001A1 (es) |
| PE (1) | PE20011308A1 (es) |
| PL (1) | PL357906A1 (es) |
| PT (1) | PT1280522E (es) |
| SK (1) | SK15132002A3 (es) |
| SV (1) | SV2002000367A (es) |
| TN (1) | TNSN01061A1 (es) |
| WO (1) | WO2001080847A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1045691T1 (en) * | 1997-12-12 | 2005-04-30 | Warner-Lambert Company Llc | Statin-carboxyalkylether combinations |
| RU2468013C2 (ru) * | 2007-06-21 | 2012-11-27 | Актимис Фармасьютикалз, Инк. | Аминовые соли антагониста crth2 |
| DE102008026033B4 (de) * | 2008-05-30 | 2017-08-24 | Voith Patent Gmbh | Antriebsstrang mit einer hydrodynamischen Maschine |
| SI23149A (sl) * | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
-
2001
- 2001-03-22 NZ NZ521713A patent/NZ521713A/en unknown
- 2001-03-22 CN CN01808632A patent/CN1426299A/zh active Pending
- 2001-03-22 EP EP01920625A patent/EP1280522B1/en not_active Expired - Lifetime
- 2001-03-22 HU HU0300403A patent/HUP0300403A3/hu unknown
- 2001-03-22 EE EEP200200611A patent/EE200200611A/xx unknown
- 2001-03-22 CA CA002405559A patent/CA2405559A1/en not_active Abandoned
- 2001-03-22 BR BR0110234-6A patent/BR0110234A/pt not_active IP Right Cessation
- 2001-03-22 WO PCT/US2001/009088 patent/WO2001080847A2/en not_active Ceased
- 2001-03-22 SK SK1513-2002A patent/SK15132002A3/sk not_active Application Discontinuation
- 2001-03-22 KR KR1020027014357A patent/KR20020091245A/ko not_active Withdrawn
- 2001-03-22 IL IL15247401A patent/IL152474A0/xx unknown
- 2001-03-22 AT AT01920625T patent/ATE283691T1/de not_active IP Right Cessation
- 2001-03-22 HR HRP20020936 patent/HRP20020936A2/hr not_active Application Discontinuation
- 2001-03-22 EA EA200200953A patent/EA005245B1/ru not_active IP Right Cessation
- 2001-03-22 OA OA1200200325A patent/OA12252A/en unknown
- 2001-03-22 AP APAP/P/2002/002665A patent/AP2002002665A0/en unknown
- 2001-03-22 JP JP2001577946A patent/JP2003531170A/ja active Pending
- 2001-03-22 PL PL01357906A patent/PL357906A1/xx not_active Application Discontinuation
- 2001-03-22 MX MXPA02009662A patent/MXPA02009662A/es unknown
- 2001-03-22 PT PT01920625T patent/PT1280522E/pt unknown
- 2001-03-22 AU AU2001247658A patent/AU2001247658A1/en not_active Abandoned
- 2001-03-22 CZ CZ20023459A patent/CZ20023459A3/cs unknown
- 2001-03-22 DE DE60107559T patent/DE60107559T2/de not_active Expired - Fee Related
- 2001-03-22 ES ES01920625T patent/ES2231470T3/es not_active Expired - Lifetime
- 2001-04-05 SV SV2001000367A patent/SV2002000367A/es not_active Application Discontinuation
- 2001-04-19 TN TNTNSN01061A patent/TNSN01061A1/en unknown
- 2001-04-23 PA PA20018516001A patent/PA8516001A1/es unknown
- 2001-04-24 PE PE2001000363A patent/PE20011308A1/es not_active Application Discontinuation
- 2001-04-24 DO DO2001000150A patent/DOP2001000150A/es unknown
- 2001-04-25 AR ARP010101902A patent/AR031104A1/es unknown
-
2002
- 2002-09-27 IS IS6570A patent/IS6570A/is unknown
- 2002-10-17 MA MA26872A patent/MA26894A1/fr unknown
- 2002-10-25 NO NO20025135A patent/NO20025135L/no not_active Application Discontinuation
- 2002-11-12 BG BG107264A patent/BG107264A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE391708T1 (de) | Verbindungen und gemische zur verabreichung eines aktiven agens | |
| DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
| ECSP034444A (es) | Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina | |
| BR0015605A (pt) | Composição e uso | |
| DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| AR035482A1 (es) | Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos | |
| AR028948A1 (es) | Compuestos novedosos | |
| DE69822659D1 (de) | Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| AR011116A1 (es) | Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene | |
| SV2002000969A (es) | Composicion parenteral reconstituible | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| ATE466008T1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält | |
| PA8568101A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso | |
| ATE302203T1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| SE0102055D0 (sv) | New Compounds | |
| PA8582201A1 (es) | Indoles 2,7-sustituidos | |
| UY29370A1 (es) | Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones | |
| BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
| AR031104A1 (es) | Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi | |
| ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
| ES2086528T3 (es) | Nuevos compuestos biciclicos sustituidos con amino. | |
| DE69815100D1 (de) | Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten | |
| DE60105028D1 (de) | Ruthenium (ii) verbindungen in der krebsbehandlung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |